Biolase, Inc. · OTC:BIOLQ
Biolase — Biolase Technology — April 3-4, 2012 investor conference, New York Palace Hotel, New York City
28 slides from Biolase's conference presentation, Apr 4, 2012
Slide 1: Fred Furry, COO & CFO
Exhibit 99.1 April 3-4, 2012 • New York Palace Hotel, New York City Fred Furry, COO & CFO NASDAQ: BLTI www.biolase.com
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation may contain forward-looking statements that are based on our current expectations, estimates and projections about our industry as well as management’s beliefs and assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “e
Slide 3: BIOLASE is Revolutionizing Surgery in Medicine
BIOLASE is Revolutionizing Surgery in Medicine How? Through the science of WaterLase! Conventional Surgical Devices include the scalpel, high speed drill, electrosurge, electric bone saws, and heat generating lasers. • The Er,Cr:YSGG (2780nm) laser crystal has the highest level of absorption in wate
Slide 4: Becoming a Globally Diversified Platform Company
Becoming a Globally Diversified Platform Company In 2011: Single Product Company In 2012: Broaden Platform and Product Portfolio 1. Moved from global exclusive distribution model with 1. Diversify revenue base to expand addressable markets Schein to direct sales and multi-distributor model. and redu
Slide 5: BIOLASE is the World Leader in Laser Dentistry
BIOLASE is the World Leader in Laser Dentistry… …and the Dental Community is the Largest Medical Community in the World! US Dental Laser Market: US Overall Dental Laser Market: Hard Tissue Hard & Soft Tissue BIOLASE ~45% BIOLASE ~80% Source: Biolase Technology Licensing Reports Source: iData Researc
Slide 6: Traditional Dentistry
Traditional Dentistry The painting Cavadenti, the Tooth Puller, by Caravaggio, circa 1608 PAGE 6
Slide 7: Current Line of BIOLASE Products
Current Line of BIOLASE Products All-tissue dental lasers: Our all-tissue lasers include our new flagship laser, the revolutionary WaterLase iPlus, and the WaterLase MDX. Diode soft-tissue dental lasers: Our soft tissue lasers include the ezLase total diode solution, which offers power and portabili
Slide 8: Alternative and Advanced Hi-Tech Dentistry
Alternative and Advanced Hi-Tech Dentistry Using BIOLASE WaterLase Systems, including our new WaterLase iPlus System: The iPlus features The aiming beam on an intuitive, touch- the WaterLase does based computer not cut the tissue or screen, similar to a generate any heat. tablet personal The tissue
Slide 9: WaterLase High Speed Cutting
WaterLase High Speed Cutting PAGE 9
Slide 10: WaterLase Side by Side with Drill
WaterLase Side by Side with Drill
Slide 11: WaterLase Soft Tissue Lingual Frenectomy
WaterLase Soft Tissue Lingual Frenectomy
Slide 12: Why BIOLASE WaterLase Technology in Dentistry?
Why BIOLASE WaterLase Technology in Dentistry? Traditional high-speed drills work by FRICTION which creates HEAT which causes PAIN. This PAIN necessitates injections of ANESTHESIA which results in PAIN and NUMB LIPS. In addition, the lack of feeling from the numbing injections can lead to THERMAL DA
Slide 13: Why Dentists Should Buy a WaterLase System?
Why Dentists Should Buy a WaterLase System? …the tremendous Return on Investment! Monthly Lease Payment New Monthly Revenue Generated Approx. $1,200 $5,000 – $15,000 • WaterLase technology enables traditional dentists to perform procedures that they currently refer out to specialists or current Wate
Slide 14: $50B to $100B WaterLase Market Opportunity
$50B to $100B WaterLase Market Opportunity The WaterLase’s global market opportunity is immense… because the dental community is the largest medical community in the world. Our current market penetration is approximately 3% in the US and slightly less than 1% internationally! • 176,000 dentists in t
Slide 15: Warning: Patients Urged to Ask their Dentists About Cross Contamination
Warning: Patients Urged to Ask their Dentists About the Risk of Cross Contamination! Cross contamination is a huge threat:1,2,3,4 • The CDC defines cross-contamination as the act of spreading bacteria and viruses from one surface to another. Blood-borne viruses have the ability to live on objects an
Slide 16: The Bacterial Challenge
The Bacterial Challenge Antibiotic resistance adversely impacts the health of millions of patients every year. Of the patients receiving antibiotics, 50% receive unnecessary or redundant therapy, resulting in overuse of antibiotics.¹ Resistance to antibiotics is high among bacteria that cause seriou
Slide 17: Eliminating the Risk of Cross Contamination
Eliminating the Risk of Cross Contamination BIOLASE is entering a new dental category utilizing WaterLase technology as it essentially eliminates the risk of cross contamination and contagion: WaterLase MD™ reduced E. faecalis 2.86 Burs and Endo Files: WaterLase Tips: times more effectively than NaO
Slide 18: Patent Portfolio
Patent Portfolio Current Status: BIOLASE has a tremendous IP portfolio with 285 issued and pending patents, 70% of which are related to our core WaterLase (Er,Cr:YSGG) technology and medical lasers. Issued Pending Total U.S. 84 53 137 International 77 71 148 Total 161 124 285 Filing costs and mainte
Slide 19: Further Opportunities to Expand in Dentistry
Further Opportunities to Expand in Dentistry Patented laser toothbrush for home use: • BIOLASE is currently engaged in discussions with The Proctor and Gamble Company (“P&G”) to develop a laser toothbrush for home use using our patents which will whiten teeth, disinfect teeth and gums, bio- stimulat
Slide 20: Digital Imaging
Digital Imaging Cone Beam Computed Tomography (CBCT) 3D Imaging: We offer the Cefla NewTom VGi and the BIOLASE DaVinci D3D digital CBCTs. These systems are a vast improvement over traditional x-ray imaging technologies and offer tremendous clinical and diagnostic advantages to dentists. CBCTs allow
Slide 21: Diversification in 2012
Diversification in 2012 BIOLASE will continue to add new products and diversify in 2012: 2011 (Projected) 2012 (Projected) WaterLase Systems ~60% ~60% Diode Systems ~20% ~15% Consumables & Other ~20% ~20% Digital Imaging Products ~0% ~5% • We expect WaterLase sales to continue grow in 2012, primaril
Slide 22: 2012: Expanding Beyond Dentistry
2012: Expanding Beyond Dentistry With our patented WaterLase and diode technologies, we have created technological platforms that have the ability to extend far outside of dentistry. We expect to greatly expand our addressable markets in the coming years which, we believe, has the potential to subst
Slide 23: 2012: Expanding Beyond Dentistry (Continued)
2012: Expanding Beyond Dentistry (Continued) Aesthetics: We have various FDA approvals for applications in dermatology, plastic surgery, and oculoplastics and are currently investigating options for entering these markets in 2012. Pain Management: We anticipate launching a new deep-tissue hand piece
Slide 24: Quarterly Revenues
Quarterly Revenues (in Millions) 2004 2005 2006 2007 2008 2009 2010 2011 Q1-Mar $ 14.5 $ 16.8 $ 16.9 $ 15.1 $ 19.0 $ 6.6 $ 4.4 $ 10.6 Q2-Jun $ 14.7 $ 14.5 $ 15.9 $ 18.2 $ 18.7 $ 14.3 $ 5.9 $ 12.1 Q3-Sep $ 12.0 $ 11.7 $ 17.1 $ 12.8 $ 15.3 $ 12.1 $ 6.2 $ 13.1 Q4-Dec $ 19.1 $ 19.0 $ 19.8 $ 20.8 $ 11.6
Slide 25: Quarterly Non-GAAP Net Income
Quarterly Non-GAAP Net Income (in Millions) 2004 2005 2006 2007 2008 2009 2010 2011 Q1-Mar $ 0.783 $ (4.015) $ (1.462) $ (0.890) $ 0.985 $ (3.763) $ (4.797) $ 0.153 Q2-Jun $ 1.006 $ (6.222) $ (1.340) $ (0.089) $ 1.578 $ 3.020 $ (3.657) $ 0.069 Q3-Sep $ (0.962) $ (4.820) $ (0.167) $ (2.765) $ (3.551)
Slide 26: Chart & Financial History
Chart & Financial History 1994-Aug 2006 reams basa meray itnership with Henry Schein i the Chante fo me 205 Aun 200 Board and CEC $000 We Ww $70,000 1 30 $60,000 ‘ $50,000 n $15 , é $40,000 Aug 2010 5 Pignatelli i $30,000 Prot he aoe $10 E ’ Rec'd for = Wikase $20,000 és $10,000 - 9 | . ; 1998 ©1999
Slide 27: Executive Management
Executive Management Federico Pignatelli has served as our CEO since August 2010, and as our Chairman of the Board and CEO since September 2010. Mr. Pignatelli is a >5% shareholder and has been active in the Company as a director and various other management roles since 1991. He also the founder, an
Slide 28: BIOLASE Today
BIOLASE Today • Our 57,000 sq. ft. corporate HQ in Irvine houses finance & administrative, sales, marketing, customer care, training, manufacturing, and R&D. This facility can accommodate growth to $250 million. • ISO 9001 certified and FDA GMP with clean room operations. Company Headquarters in Irv